Phibro Animal Health CORP 8-K filings

Phibro Animal Health Corporation announced the declaration of its quarterly cash dividend of $0.12 per share for both Class A and Class B common stock.

Phibro Animal Health Corporation has appointed Daniel Bendheim as CEO and President, effective July 1, 2026, with a performance-based compensation package.

Phibro Animal Health Corporation announced robust third quarter results with a 10% increase in net sales and a 15% rise in net income, leading to an upward revision of its full fiscal year 2026 financial guidance.

Phibro Animal Health Corporation announced the declaration of a quarterly cash dividend of $0.12 per share on its common stock.

Phibro Animal Health Corporation announced a new Brazilian regulatory framework for antimicrobials, expecting limited impact on fiscal 2026 results.

Phibro Animal Health Corporation announces the upcoming resignation of Director Joyce J. Lee, effective April 15, 2026, citing no disagreements with the company.

Phibro Animal Health Corporation reported robust second-quarter results, driven by strong sales across its Animal Health segment, leading to a significant increase in net income and an upward revision of its full-year fiscal 2026 financial guidance.

Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share for Class A and Class B common stock.

Phibro Animal Health Corporation announced a leadership transition with Jack C. Bendheim stepping down as CEO and President, effective July 1, 2026, to become Executive Chairman, and Daniel Bendheim appointed as the new CEO and President.

Phibro Animal Health reported a strong first quarter with significant sales and earnings growth, leading to an upward revision of its fiscal year 2026 Adjusted EBITDA guidance.

Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock.

Phibro Animal Health Corporation reports exceptional fourth-quarter and full-year fiscal 2025 results, driven by strong demand and a successful acquisition, while providing robust FY2026 guidance.

Phibro Animal Health Corporation's Board of Directors declared a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock.

Phibro Animal Health Corporation announces a 32% increase in net sales and an 85% surge in adjusted EBITDA for the third quarter ended March 31, 2025, while also updating its financial guidance for the fiscal year.

Phibro Animal Health Corporation declares a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock.

Phibro Animal Health Corporation announces a significant increase in net sales and adjusted EBITDA for the second quarter ended December 31, 2024, and updates its financial guidance for fiscal year 2025.

Phibro Animal Health Corporation declares a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock.

Phibro Animal Health Corporation has appointed Joyce J. Lee as a Class II director, effective January 21, 2025, filling a current vacancy and increasing board membership to nine.

Phibro Animal Health Corporation finalizes the acquisition of Zoetis's medicated feed additive product portfolio for $305 million, marking a significant expansion in its animal health business.

Phibro Animal Health Corporation has announced the retirement of Rob Aukerman, President of the North America Region, and the appointment of Todd Armstrong as his successor, effective January 1, 2025.

Phibro Animal Health Corporation announced a strong first quarter with significant increases in net sales, net income, and adjusted EBITDA, and updated its financial guidance for fiscal year 2025.

Phibro Animal Health Corporation has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock.

Phibro Animal Health Corporation finalized its acquisition of Zoetis' medicated feed additive portfolio and certain water-soluble products for $350 million, funded by new debt.

Phibro Animal Health Corporation announced its fourth quarter and full fiscal year 2024 results, showing a mixed performance with increased sales but decreased net income, while providing positive financial guidance for fiscal year 2025.

Phibro Animal Health Corporation has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock.

Phibro Animal Health Corporation has entered into a new $1 billion credit agreement to refinance existing debt and support working capital needs and a recent acquisition.

Phibro Animal Health Corporation announced a 7% increase in net sales for the third quarter, driven by strong performance in its Animal Health segment, while updating its full-year financial guidance to reflect acquisition-related expenses.

Phibro Animal Health Corporation has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock.

Phibro Animal Health has agreed to acquire Zoetis' medicated feed additive portfolio, certain water soluble products, and related assets for $350 million, significantly expanding its product offerings and global reach.

Phibro Animal Health Corporation announced a 2% increase in net sales for the second quarter of fiscal year 2024, alongside a decrease in net income and updated financial guidance.